425 related articles for article (PubMed ID: 33070839)
1. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy.
Ando S; Osanai D; Takahashi K; Nakamura S; Shimazawa M; Hara H
J Pharmacol Sci; 2020 Dec; 144(4):204-211. PubMed ID: 33070839
[TBL] [Abstract][Full Text] [Related]
2. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
[TBL] [Abstract][Full Text] [Related]
3. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
[TBL] [Abstract][Full Text] [Related]
4. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
5. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
6. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
7. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F
J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328
[TBL] [Abstract][Full Text] [Related]
8. Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.
Tseng YT; Chen CS; Jong YJ; Chang FR; Lo YC
Pharmacol Res; 2016 Sep; 111():58-75. PubMed ID: 27241020
[TBL] [Abstract][Full Text] [Related]
9. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage.
Jangi M; Fleet C; Cullen P; Gupta SV; Mekhoubad S; Chiao E; Allaire N; Bennett CF; Rigo F; Krainer AR; Hurt JA; Carulli JP; Staropoli JF
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):E2347-E2356. PubMed ID: 28270613
[TBL] [Abstract][Full Text] [Related]
10. Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment.
Sintusek P; Catapano F; Angkathunkayul N; Marrosu E; Parson SH; Morgan JE; Muntoni F; Zhou H
PLoS One; 2016; 11(5):e0155032. PubMed ID: 27163330
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
12. Decreased Motor Neuron Support by SMA Astrocytes due to Diminished MCP1 Secretion.
Martin JE; Nguyen TT; Grunseich C; Nofziger JH; Lee PR; Fields D; Fischbeck KH; Foran E
J Neurosci; 2017 May; 37(21):5309-5318. PubMed ID: 28450545
[TBL] [Abstract][Full Text] [Related]
13. A combinatorial approach increases SMN level in SMA model mice.
Dumas SA; Villalón E; Bergman EM; Wilson KJ; Marugan JJ; Lorson CL; Burnett BG
Hum Mol Genet; 2022 Aug; 31(17):2989-3000. PubMed ID: 35419606
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
[TBL] [Abstract][Full Text] [Related]
16. Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy.
Comley LH; Kline RA; Thomson AK; Woschitz V; Landeros EV; Osman EY; Lorson CL; Murray LM
Hum Mol Genet; 2022 Sep; 31(18):3107-3119. PubMed ID: 35551393
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
[TBL] [Abstract][Full Text] [Related]
18. Proteomic assessment of a cell model of spinal muscular atrophy.
Wu CY; Whye D; Glazewski L; Choe L; Kerr D; Lee KH; Mason RW; Wang W
BMC Neurosci; 2011 Mar; 12():25. PubMed ID: 21385431
[TBL] [Abstract][Full Text] [Related]
19. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models.
Kim JK; Jha NN; Feng Z; Faleiro MR; Chiriboga CA; Wei-Lapierre L; Dirksen RT; Ko CP; Monani UR
J Clin Invest; 2020 Mar; 130(3):1271-1287. PubMed ID: 32039917
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
